New Data Reinforce Favorable Safety, Efficacy Of Roche's Hemlibra For Hemophilia A

• Roche Holdings AG (OTC: RHHBY) announced results from the primary analysis of the phase 3 HAVEN 6 study of Hemlibra (emicizumab) in people with moderate or mild hemophilia A.

• The data showed that Hemlibra demonstrated a favorable safety profile and effective bleed control in patients without factor VIII inhibitors.

• The primary analysis included data from 72 participants who warranted prophylaxis.

• The data show that Hemlibra maintained low treated bleed rates across the study period, with 66.7% of participants experiencing no bleeds that required treatment at 55.6 weeks median follow-up.

• 81.9% experienced no spontaneous bleeds that required treatment, and 88.9% experienced no joint bleeds that required treatment.

• Annualized bleed rates remained low throughout the evaluation period at 0.9.

• Local injection site reactions were the most common adverse event related to treatment.

• One participant experienced a grade one thromboembolic event unrelated to Hemlibra.

• Price Action: RHHBY shares are up 0.73% at $41.43 during the market session on the last check Monday.

See more from Benzinga

• The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death

• Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.